There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Matinas BioPharma (MTNB – Research Report) and Spruce Biosciences (SPRB – Research Report) with bullish sentiments.
Matinas BioPharma (MTNB)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Matinas BioPharma yesterday. The company’s shares closed last Friday at $0.46, close to its 52-week low of $0.43.
According to TipRanks.com, McCarthy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Matinas BioPharma with a $3.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Spruce Biosciences (SPRB)
In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Spruce Biosciences, with a price target of $7.00. The company’s shares closed last Friday at $2.28.
According to TipRanks.com, Wolleben is a 4-star analyst with an average return of
Currently, the analyst consensus on Spruce Biosciences is a Strong Buy with an average price target of $9.75, which is a 327.6% upside from current levels. In a report released today, Credit Suisse also reiterated a Buy rating on the stock with a $4.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MTNB:
- Matinas BioPharma Reports 2022 Financial Results and Provides a Business Update
- Matinas BioPharma to Webcast Conference Call to Discuss 2022 Financial Results and Provide a Business Update on March 15, 2023
- Matinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMID
- Matinas BioPharma to hold a corporate update conference call
- Matinas BioPharma provides business update, cash position
